Anuj Mahindra, M.D.

Publications

Mahindra A, Anderson KC.Role of Interleukin 16 in Multiple Myeloma Pathogenesis: * A Potential Novel Therapeutic Target?.Journal of the National Cancer Institute. 2012 Jun 28.
22745468
Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K.Latest advances and current challenges in the treatment of multiple myeloma.Nat Rev Clin Oncol. 2012 Feb 21.
22349016
Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Har
22042147
Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).Eur J Haematol. 2011 Oct 12.
21991938
Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.Management of relapsed and relapsed/refractory multiple myeloma.J Natl Compr Canc Netw. 2011 Oct;9(10):1209-
21975917
Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E.Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization w
21460870
Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via
21430070
Mahindra A, Hideshima T, Anderson KC.Multiple myeloma: biology of the disease.Blood Rev. 2010 Nov;24 Suppl 1:S5-11.
21126636
Weaver J, Mahindra AK, Pohlman B, Jin T, Hsi ED.Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.J Cutan Pathol. 2010 May;37(5):516-24.
20132421
Mahindra A, Cirstea D, Raje N.Novel therapeutic targets for multiple myeloma.Future Oncol. 2010 Mar;6(3):407-18. Review.
20222797
Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D
20118399
Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia. 2009 Dec;23(12):2222-32. Review.
19741729
Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Kalaycio M, Sweetenham J, Bolwell B, Copelan E.Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation.Bone Marrow Tr
19377514
Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
19878638
Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloabla
19508292
Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.Biol Blood Marrow Transplant
18940678
Kalmadi S, Baz R, Mahindra A.Lenalidomide: the emerging role of a novel targeted agent in malignancies.Drugs Today. 2007 Feb;43(2):85-95. Review.
17353946
Mahindra AK, Grossman SA.Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.J. Neurooncol. 2003 Jul;63(3):263-70.
12892232

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Anuj Mahindra, M.D. Publications Mahindra A, Anderson KC.Role of Interleukin 16 in Multiple Myeloma Pathogenesis: * A Potential Novel Therapeutic Target?.Journal of the National Cancer Institute. 2012 Jun 28. 22745468 Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K.Latest advances and current challenges in the treatment of multiple myeloma.Nat Rev Clin Oncol. 2012 Feb 21. 22349016 Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Har 22042147 Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms(*).Eur J Haematol. 2011 Oct 12. 21991938 Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.Management of relapsed and relapsed/refractory multiple myeloma.J Natl Compr Canc Netw. 2011 Oct;9(10):1209- 21975917 Mahindra A, Bolwell BJ, Rybicki L, Elder P, Kalaycio M, Dean R, Avalos B, Sobecks R, Tench S, Andresen S, Pohlman B, Sweetenham J, Devine S, Copelan E.Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization w 21460870 Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via 21430070 Mahindra A, Hideshima T, Anderson KC.Multiple myeloma: biology of the disease.Blood Rev. 2010 Nov;24 Suppl 1:S5-11. 21126636 Weaver J, Mahindra AK, Pohlman B, Jin T, Hsi ED.Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.J Cutan Pathol. 2010 May;37(5):516-24. 20132421 Mahindra A, Cirstea D, Raje N.Novel therapeutic targets for multiple myeloma.Future Oncol. 2010 Mar;6(3):407-18. Review. 20222797 Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D 20118399 Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia. 2009 Dec;23(12):2222-32. Review. 19741729 Mahindra A, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Kalaycio M, Sweetenham J, Bolwell B, Copelan E.Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation.Bone Marrow Tr 19377514 Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review. 19878638 Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloabla 19508292 Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.Biol Blood Marrow Transplant 18940678 Kalmadi S, Baz R, Mahindra A.Lenalidomide: the emerging role of a novel targeted agent in malignancies.Drugs Today. 2007 Feb;43(2):85-95. Review. 17353946 Mahindra AK, Grossman SA.Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.J. Neurooncol. 2003 Jul;63(3):263-70. 12892232
Site Map Site Feedback Web Privacy Policy